COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00688454
Recruitment Status : Completed
First Posted : June 3, 2008
Last Update Posted : April 9, 2009
Information provided by:

Brief Summary:
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR

Condition or disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 3392 participants
Time Perspective: Prospective
Official Title: C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
Study Start Date : February 2007
Actual Study Completion Date : January 2008

Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia

Primary Outcome Measures :
  1. LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin [ Time Frame: 3 visits within 10 weeks ]

Secondary Outcome Measures :
  1. Tolerability of CRESTOR-therapy [ Time Frame: 3 visits within 10 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients

Inclusion Criteria:

  • Patients with hypercholesteremia who was never treated with statins before
  • Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion Criteria:

  • None

Layout table for additonal information
Responsible Party: Dr med Madeleine Billeter, AstraZeneca AG, Switzerland Identifier: NCT00688454    
Other Study ID Numbers: NIS-CCH-CRE-2007/1
First Posted: June 3, 2008    Key Record Dates
Last Update Posted: April 9, 2009
Last Verified: April 2009
Keywords provided by AstraZeneca:
CRESTOR therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors